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background:  Primary percutaneous coronary intervention (PPCI) within the recommended guidelines time window cannot be offered to 
all patients with ST-elevation myocardial infarction (STEMI). Currently, the role of pharmaco-invasive strategy in STEMI treatment remains 
uncertain with limited but promising data. We performed a meta-analysis of all available data (randomized controlled trials and cohort 
studies) comparing pharmaco-invasive strategy versus PPCI strategy in STEMI patients to better characterize the role of pharmaco-
invasive strategy for the treatment of STEMI. 
methods:  We systematically searched MEDLINE, EMBASE, and Cochrane Library (up to June 2014) for studies comparing the two 
reperfusion strategies. The primary composite outcome consisted of all-cause mortality, reinfarction, and stroke at 30 days. The primary 
efficacy outcomes were 30-day all-cause mortality and reinfarction. We also analyzed these efficacy outcomes at the 6-12 month follow-up. 
The safety outcomes included stroke and major bleeding at 30 days. 
Results:  We identified seven eligible trials including 4220 STEMI patients, of whom 2271 (53.8%) received pharmaco-invasive therapy 
and 1949 (46.2%) received PPCI.The overall pooled results showed that there was no significant difference between the two strategies 
in the combined outcome of all-cause mortality, reinfarction, and stroke at 30 days (OR: 1.03, 95% CI: 0.8-1.33; P = 0.80). Moreover, 
no significant differences were observed between both approaches in all-cause mortality (OR: 0.94, 95% CI: 0.69-1.29; P =0.72) and 
reinfarction (OR: 1.38, 95% CI: 0.88-2.18; P = 0.18) at 30 days, and all-cause mortality (OR: 0.90, 95% CI: 0.69-1.17; P =0.44) and 
reinfarction (OR: 1.22, 95% CI: 0.43-3.47; P = 0.71) at 6-12 months. Stroke (OR: 2.25, 95% CI: 1.14-4.46; P =0.02) and major bleeding 
events (OR, 1.29; 95% CI, 0.93 to 1.80; P = 0.13) were slightly higher in the pharmaco-invasive therapy group than in the PPCI group. 
conclusion:  Our findings suggest that pharmaco-invasive therapy for STEMI offers similar clinical efficacy outcomes to those of PPCI, but 
STEMI patients who receive pharmaco-invasive therapy might suffer more stroke and bleeding events.
